nuroflux are developing a wearable device for the continuous monitoring of stroke patients.
Following a suspected stroke, a CT scan will be used to confirm the diagnosis. CT scans provide imaging snapshots but due to radiation exposure are only performed every 24 hours. In this first 24-hour window, patients will receive treatment and are at risk of having a secondary stroke. However, there is currently no device for the continuous monitoring of these patients.
Our device will fill this gap, proving real-time monitoring of patient’s cerebral blood flow and brain activity in-between CT scans to inform on treatment outcome and detect secondary strokes.
Founder Sam van Bohemen has a neuroscience background and is currently completing a PhD in biomedical engineering. Sam is supported by advisors with experience in engineering, clinical care of patients, commercialisation, regulatory affairs and market access.
